Spire Healthcare Group plc (LON:SPI - Get Free Report) traded up 16.4% on Friday . The stock traded as high as GBX 256.50 ($3.47) and last traded at GBX 252 ($3.41). 39,487,281 shares changed hands during trading, an increase of 2,319% from the average session volume of 1,632,481 shares. The stock had previously closed at GBX 216.50 ($2.93).
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Spire Healthcare Group from GBX 309 to GBX 303 and set an "overweight" rating for the company in a report on Tuesday, August 5th. Berenberg Bank reaffirmed a "buy" rating and set a GBX 280 price objective on shares of Spire Healthcare Group in a report on Thursday, July 31st. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of GBX 294.33.
Check Out Our Latest Report on SPI
Spire Healthcare Group Stock Up 3.6%
The company has a market cap of £981.79 million, a price-to-earnings ratio of 5,304.35, a price-to-earnings-growth ratio of 1.06 and a beta of 0.96. The company has a current ratio of 0.70, a quick ratio of 0.74 and a debt-to-equity ratio of 62.25. The firm's fifty day moving average price is GBX 218.99 and its 200-day moving average price is GBX 203.96.
Spire Healthcare Group (LON:SPI - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported GBX 4.10 earnings per share (EPS) for the quarter. Spire Healthcare Group had a net margin of 1.96% and a return on equity of 3.82%. Sell-side analysts predict that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current year.
About Spire Healthcare Group
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Further Reading
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
